Nacuity Pharmaceuticals Reports Encouraging Results in Retinitis Pigmentosa Trial
FORT WORTH, TX – September 13, 2025 – Nacuity Pharmaceuticals today announced promising data from a clinical trial assessing NPI-001 as a treatment for retinitis pigmentosa (RP) linked to Usher syndrome. The findings, revealed at a medical conference, demonstrate the potential of NPI-001 to preserve adn, in some cases, improve vision in individuals grappling with this progressive degenerative eye disease.
Retinitis pigmentosa, affecting approximately 1 in 4,000 people globally, leads to gradual vision loss due to the deterioration of photoreceptor cells in the retina. Usher syndrome, a genetic condition often causing both hearing loss and RP, presents a especially challenging prognosis. This trial’s positive results offer renewed hope for those living with this debilitating dual-sensory impairment,potentially slowing disease progression and extending functional vision. Nacuity is continuing to analyze the data and plans further development of NPI-001.
The ongoing clinical program evaluating NPI-001 is one of three highly differentiated programs underway at Nacuity, which also focuses on treatments for cataract and cystinosis. The company, with operations in Fort Worth, Texas, and australia, benefits from considerable managerial and scientific expertise. It also receives support from the Foundation Fighting Blindness and its venture arm, RD Fund.
Further information about Nacuity Pharmaceuticals and its research can be found at www.nacuity.com.
media Contact:
Julia Clements
6 Degrees
267.626.1085
jclements@6degreespr.com
